CA3139508A1 - Materials and methods for modulating t cell mediated immunity - Google Patents

Materials and methods for modulating t cell mediated immunity Download PDF

Info

Publication number
CA3139508A1
CA3139508A1 CA3139508A CA3139508A CA3139508A1 CA 3139508 A1 CA3139508 A1 CA 3139508A1 CA 3139508 A CA3139508 A CA 3139508A CA 3139508 A CA3139508 A CA 3139508A CA 3139508 A1 CA3139508 A1 CA 3139508A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139508A
Other languages
English (en)
French (fr)
Inventor
Rajkumar Ganesan
Iqbal S. Grewal
Sanjaya Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA3139508A1 publication Critical patent/CA3139508A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3139508A 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity Pending CA3139508A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962844959P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US62/844,959 2019-05-08
US62/844,966 2019-05-08
US62/844,976 2019-05-08
US62/844,995 2019-05-08
US62/844,970 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
CA3139508A1 true CA3139508A1 (en) 2020-11-12

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139508A Pending CA3139508A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Country Status (22)

Country Link
US (2) US11667712B2 (https=)
EP (1) EP3965818A4 (https=)
JP (2) JP7686571B2 (https=)
KR (1) KR20220017892A (https=)
CN (1) CN113966231B (https=)
AU (1) AU2020267504A1 (https=)
BR (1) BR112021022089A2 (https=)
CA (1) CA3139508A1 (https=)
CL (1) CL2021002905A1 (https=)
CO (1) CO2021015998A2 (https=)
CR (1) CR20210548A (https=)
DO (1) DOP2021000229A (https=)
EC (1) ECSP21087921A (https=)
IL (1) IL287817A (https=)
JO (1) JOP20210297A1 (https=)
MA (1) MA55903A (https=)
MX (1) MX2021013532A (https=)
PE (1) PE20220763A1 (https=)
PH (1) PH12021552790A1 (https=)
SG (1) SG11202112021QA (https=)
TW (1) TW202108618A (https=)
WO (1) WO2020227457A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CA3145523A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
KR20220147631A (ko) * 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
US11639396B2 (en) * 2021-02-16 2023-05-02 Janssen Biotech, Inc. Antibody binding to a linker peptide
MX2023009950A (es) 2021-02-26 2023-11-10 Lava Therapeutics N V Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta.
IL326116A (en) * 2023-07-26 2026-03-01 Janssen Biotech Inc Materials and methods for cell culture
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
BR112013002831A2 (pt) 2010-08-05 2016-11-01 Anaptysbio Inc anticorpos direcionados contra a il-17
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
EP3129404B1 (en) 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EP3560955A4 (en) 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g

Also Published As

Publication number Publication date
US20210032338A1 (en) 2021-02-04
PE20220763A1 (es) 2022-05-16
CL2021002905A1 (es) 2022-06-17
ECSP21087921A (es) 2022-01-31
CN113966231A (zh) 2022-01-21
KR20220017892A (ko) 2022-02-14
SG11202112021QA (en) 2021-11-29
EP3965818A4 (en) 2023-05-31
US20240150464A1 (en) 2024-05-09
EP3965818A1 (en) 2022-03-16
JP7686571B2 (ja) 2025-06-02
PH12021552790A1 (en) 2022-09-05
CR20210548A (es) 2022-02-11
AU2020267504A1 (en) 2021-12-02
JP2024170410A (ja) 2024-12-10
IL287817A (en) 2022-01-01
DOP2021000229A (es) 2022-07-31
CN113966231B (zh) 2025-04-01
WO2020227457A1 (en) 2020-11-12
TW202108618A (zh) 2021-03-01
BR112021022089A2 (pt) 2022-02-08
US11667712B2 (en) 2023-06-06
JOP20210297A1 (ar) 2023-01-30
MA55903A (fr) 2022-03-16
CO2021015998A2 (es) 2021-12-10
JP2022533538A (ja) 2022-07-25
MX2021013532A (es) 2022-02-11

Similar Documents

Publication Publication Date Title
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity
US20240218076A1 (en) Therapeutic antibodies
CA2684626C (en) Penta-specific antibodies binding il-8, gro-alpha, gro-beta, gro-gamma and ena-78
CA3198590A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
US20170210802A1 (en) Multispecific antigen binding proteins
CN113573728A (zh) 治疗性SIRPα抗体
IL295295A (en) Antibodies targeting fc receptor-like 5 and methods of use
CA3199767A1 (en) Compositions and methods for modulating delta gamma chain mediated immunity
CA3120793A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
CN113056487A (zh) 抗tnfr2抗体及其用途
CN116234572A (zh) 治疗性SIRPα抗体
JP7430137B2 (ja) 抗体および使用方法
KR20240036142A (ko) 3특이성 및/또는 3가 결합 단백질
CN118638234A (zh) 抗bdca2抗体及其制备方法和应用
JP2025537255A (ja) 抗アルファ５インテグリン抗体及びその使用
US20250340632A1 (en) SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIES
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
CN114773467B (zh) 抗SIRPα抗体或其抗原结合片段及应用
KR20240113488A (ko) 신규 항-il-36r 항체
TW202521578A (zh) Ｂｔｎ３ａ結合蛋白及其醫藥用途
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220617

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250502

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401